BCM
BIIB icon

Brooktree Capital Management’s Biogen BIIB Stock Holding History

Brooktree Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-820
Closed -$259K – 54
2020
Q1 		$259K Sell
820
-157
-16% -$47.6K 0.3% 46
2019
Q4 		$290K Buy
+977
New +$271K 0.27% 50

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brooktree Capital Management's BIIB Position: Q2 2020 in Review

Brooktree Capital Management sold out of Biogen (BIIB) in Q2 2020, closing a stake of 820 shares — an estimated $259K sold.

Brooktree Capital Management first reported a position in BIIB in Q4 2019 and held it in 2 quarters. The position peaked at $290K in Q4 2019. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

  • Brooktree Capital Management reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
  • Brooktree Capital Management sold 820 Biogen shares in Q2 2020, an estimated $259K.
  • Brooktree Capital Management first reported a position in Biogen in Q4 2019 and held it in 2 quarters.
  • Brooktree Capital Management's Biogen position peaked at $290K in Q4 2019.
  • 1,060 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Brooktree Capital Management's 13F filing for Q2 2020, filed 3 Aug 2020.